Compare Quanta Services Inc (PWR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs TG Therapeutics Inc — how do they compare? Quanta Services Inc trades at $700.31 (market cap $103.03B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Quanta Services Inc is far larger — about 12.6× TG Therapeutics Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and TG Therapeutics Inc for 16 Days on average.
| PWR | TGTX | |
|---|---|---|
Market Cap | $103.03B | $8.16B |
Volume | 977,892 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $785.24 | $59.06 |
52-Week Low | $412.21 | $26.94 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $109.13B | $8.37B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $701.01, down slightly by 0.01% on the day, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. A record backlog of $53B and positive news on AI infrastructure demand highlight near-term catalysts.
Outlook is positive given earnings momentum and sector tailwinds, but high valuation ratios (P/E of 78.41) and execution risks on large projects pose challenges. With 75% of analysts rating it a Buy and a consensus price target of $802.08, upside potential exists if growth sustains.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
